特地唑胺置于三乙胺,三氯氧磷,水体系中,用 四氢呋喃 作为反应溶剂,化学反应 4.6H,反应生成 磷酸特地唑胺 参考文献: Methods Of Treating Subjects With Renal Impairment Using Tedizolid[fr] Procédés De Traitement De Sujets Présentant Une Insuffisance Rénale à L'Aide De Tédizolid 标题: Methods Of Treating Subjects With Renal Impairment Using Tedizolid[fr] Procédés De Traitement De Sujets Présentant Une Insuffisance Rénale à L'Aide De Tédizolid 摘要:本公开涉及将泰利唑胺用于特殊患者人群,例如患有肾功能障碍的患者,以治疗感染的目的.
专利号:US-8461188-B2 优先权日:2011-10-20 标题 :Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use 发明人:BARTIZAL KENNETH F; LOCKE JEFFREY B; SHAW KAREN JOY; PROKOCIMER PHILIPPE G 权利人:TRIUS THERAPEUTICS INC 摘要:A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.
专利号:CN-107382995-A 优先权日:2017-09-01 标 题 :One-pot synthesis of tedizolid
专利号:EP-2757104-B1 优先权日:2008-10-10 标题 :Compounds used in the synthesis of oxazolidinones
专利号:ES-2744907-T3 优先权日:2008-10-10 标 题:Compounds used in the synthesis of oxazolidinones
专利号:US-2019352262-A1 优先权日:2017-02-01 标题 :New Pleuromutilin Antibiotic Compounds, Compositions and Methods of Use and Synthesis 发明人:HERZON SETH; MURPHY STEPHEN K; ZENG MINGSHUO 权利人:UNIV YALE 摘要:The present invention is directed to novel pleuroniutilin antibiotic compounds, intermediates which are useful for making these novel amibioiic compounds and related methods and pharmaceutical compositions for treating pathogens, especially bacterial infections, including gram negative bacteria and synthesizing these compounds.
专利号:US-2013102523-A1 优先权日:2011-10-20 标 题 :Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
1: Liu X, Enoki Y, Taguchi K, Matsumoto K. Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis. J Pharm Pharmacol. 2024 Nov 6:rgae124. doi: 10.1093/jpp/rgae124. Epub ahead of print. 13(9):866. doi: 10.3390/antibiotics13090866. 3: Coustilleres F, Thillard EM, Khanna RK, Olivereau S, Ouaissi M, Pansu N, Le Lez ML. Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment. Open Forum Infect Dis. 2024 Sep 24;11(9):ofae517. doi: 10.1093/ofid/ofae517.
合成参考文献
参考文献:10.1517/17425255.2015.1098617 摘要:Douros A, Grabowski K, Stahlmann R. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opinion on Drug Metabolism & Toxicology. 2015 Oct 12;11(12):1849–59. doi: 10.1517/17425255.2015.1098617. 参考文献:10.1093/jac/dkv302 摘要:Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2016 Jan;71(1):152–5. doi: 10.1093/jac/dkv302.